4NARAWADEENIAMHUN, PANOMVANA D, PONGPECHP, et al. Pharmacodynamic target associated with clinicaloutcome of hospital-acquired pneumonia treatment withefoperazone/sulbactam [J]. Int J Pharm Pharm Sci, 2012,4(Suppl 1): 584-589.
5SIPAHI O R, ARDA B,NAZLI-ZEKA A,et al. Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-riskfebrile neutropenia cases [J]. Int J Clin Pract, 2014, 68(2):230-235.
6WANG Q, WU Y X, CHEN B Y, et al. Drug concentrations inthe serum and cerebrospinal fluid of patients treated withcefoperazone/sulbactam after craniotomy [J]. BMCAnesthesiol, 2015(15): 33. Doi: 10.1186/sl2871-015-0012-l.
9SCHWARTZ J I,JAUREGUI L E, BACHMANN K A, et al.Multiple-close pharmacokinetics of intravenously administeredcefoperazone and sulbactam when given in combination toinfected, seriously ill, elderly patients [J]. Antimicrob AgentsChemother, 1988,32(5): 730-735.
10JOHNSON C A, ZIMMERMAN S W, REITBERG D P,et al.Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritonealdialysis [J]. Antimicrob Agents Chemother, 1988,32(1):51-56.
